Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00731263 · ClinicalTrials.gov registry record · Phase 1

A Study of Tor Kinase Inhibitor in Advanced Tumors

A Phase 1 study of Solid Tumors, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target
4
Study locations

NCT00731263 is a Phase 1 study of Solid Tumors that has completed, run by AstraZeneca. The registered enrollment target is 64 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00731263, a Phase 1 study of Solid Tumors, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target
4
Study locations

Study Summary

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.

Conditions Studied

Solid Tumors

Interventions

  • DRUG AZD8055

Study Locations (4)

New York

  • Research Site - New York

Texas

  • Research Site - Houston

Other

  • Research Site - Clichy

Surrey

  • Research Site - Sutton

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2008-07
Est. Completion 2010-11
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00731263

The ClinicalTrials.gov registry entry for NCT00731263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which AZD8055 is the first listed.

NCT00731263 reports 4 study locations spanning 4 distinct geographic areas - top geographies include New York, Texas, Other.

Frequently Asked Questions

What is clinical trial NCT00731263 about?

NCT00731263 is a clinical study titled "A Study of Tor Kinase Inhibitor in Advanced Tumors". The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.

What is the current status of trial NCT00731263?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2008-07. Estimated completion is 2010-11.

What conditions does trial NCT00731263 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00731263?

The interventions under investigation include: AZD8055 (DRUG).

Who is sponsoring clinical trial NCT00731263?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00731263 being conducted?

This trial has 4 study locations across New York, Texas, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.